TY - JOUR
T1 - Long-term clinical parameters after switching to nocturnal haemodialysis
T2 - A Dutch propensity-score-matched cohort study comparing patients on nocturnal haemodialysis with patients on three-times-a week haemodialysis/haemodiafiltration
AU - Jansz, Thijs Thomas
AU - Ozyilmaz, Akin
AU - Grooteman, Muriel P. C.
AU - Hoekstra, Tiny
AU - Romijn, Marieke
AU - Blankestijn, Peter J.
AU - Bots, Michael L.
AU - van Jaarsveld, Brigit C.
PY - 2018/3
Y1 - 2018/3
N2 - Objectives Nocturnal haemodialysis (NHD), characterised by 8-hour sessions >= 3 times a week, is known to improve clinical parameters in the short term compared with conventional-schedule haemodialysis (HD), generally 3x3.5-4 hours a week. We studied long-term effects of NHD and used patients on conventional HD/haemodiafiltration (HDF) as controls.Design Four-year prospective follow-up of patients who switched to NHD; we compared patients with patients on HD/HDF using propensity score matching.Setting 28 Dutch dialysis centres.Participants We included 159 patients starting with NHD any time since 2004, aged 56.7 +/- 12.9 years, with median dialysis vintage 2.3 (0.9-5.1) years. We propensity-score matched 100 patients on NHD to 100 on HD/HDF.Primary and secondary outcome measures Control of hypertension (predialysis blood pressure, number of antihypertensives), phosphate (phosphate, number of phosphate binders), nutritional status and inflammation (albumin, C reactive protein and postdialysis weight) and anaemia (erythropoiesis-stimulating agent (ESA) resistance).Results Switching to NHD was associated with a nonsignificant reduction of antihypertensives compared with HD/HDE (ORConclusions After switching to NHD, the lower need for antihypertensives, phosphate binders and ESA persists for at least 4 years. These sustained improvements in NHD contrast significantly with the course of these parameters during continued treatment with conventional-schedule HD and HOE. NHD provides an optimal form of dialysis, also suitable for patients expected to have a long waiting time for transplantation or those convicted to indefinite dialysis.
AB - Objectives Nocturnal haemodialysis (NHD), characterised by 8-hour sessions >= 3 times a week, is known to improve clinical parameters in the short term compared with conventional-schedule haemodialysis (HD), generally 3x3.5-4 hours a week. We studied long-term effects of NHD and used patients on conventional HD/haemodiafiltration (HDF) as controls.Design Four-year prospective follow-up of patients who switched to NHD; we compared patients with patients on HD/HDF using propensity score matching.Setting 28 Dutch dialysis centres.Participants We included 159 patients starting with NHD any time since 2004, aged 56.7 +/- 12.9 years, with median dialysis vintage 2.3 (0.9-5.1) years. We propensity-score matched 100 patients on NHD to 100 on HD/HDF.Primary and secondary outcome measures Control of hypertension (predialysis blood pressure, number of antihypertensives), phosphate (phosphate, number of phosphate binders), nutritional status and inflammation (albumin, C reactive protein and postdialysis weight) and anaemia (erythropoiesis-stimulating agent (ESA) resistance).Results Switching to NHD was associated with a nonsignificant reduction of antihypertensives compared with HD/HDE (ORConclusions After switching to NHD, the lower need for antihypertensives, phosphate binders and ESA persists for at least 4 years. These sustained improvements in NHD contrast significantly with the course of these parameters during continued treatment with conventional-schedule HD and HOE. NHD provides an optimal form of dialysis, also suitable for patients expected to have a long waiting time for transplantation or those convicted to indefinite dialysis.
KW - CHRONIC KIDNEY-DISEASE
KW - RANDOMIZED CONTROLLED-TRIAL
KW - STAGE RENAL-DISEASE
KW - QUALITY-OF-LIFE
KW - CONVENTIONAL HEMODIALYSIS
KW - ONLINE HEMODIAFILTRATION
KW - ALL-CAUSE
KW - CARDIOVASCULAR MORTALITY
KW - OUTCOMES
KW - CALCIFICATION
U2 - 10.1136/bmjopen-2017-019900
DO - 10.1136/bmjopen-2017-019900
M3 - Article
SN - 2044-6055
VL - 8
JO - BMJ Open
JF - BMJ Open
IS - 3
M1 - 019900
ER -